[go: up one dir, main page]

AR050374A1 - Forma polimorfica de rafampicina - Google Patents

Forma polimorfica de rafampicina

Info

Publication number
AR050374A1
AR050374A1 ARP050103448A ARP050103448A AR050374A1 AR 050374 A1 AR050374 A1 AR 050374A1 AR P050103448 A ARP050103448 A AR P050103448A AR P050103448 A ARP050103448 A AR P050103448A AR 050374 A1 AR050374 A1 AR 050374A1
Authority
AR
Argentina
Prior art keywords
degree
peak
polymorphic form
approximately
rafampicine
Prior art date
Application number
ARP050103448A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35431373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR050374(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR050374A1 publication Critical patent/AR050374A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente trata de forma polimorfica de rafampicina, procesos para preparalas y composiciones farmacéuticas que las contienen. Reivindicacion 1: Una forma polimorfa II de rapamicina teniendo: (a) un termogrma de calorimetría de exploracion diferencial que carece de un pico endodérmico de aproximadamente 194 degree ; y (b) un patron pico de difraccion de rayos X que carece de picos 2(theta) de 7,2 degree , 9,9 degree , 10,2 degree , 11,1 degree , 12,5 degree , 14,5 degree , 15,3 degree , 15,5 degree , 16,2 degree , 20,0 degree , 20,4 degree , y 21,8 degree . Reivindicacion 2: Una forma polimorfa II de rapamicina teniendo las siguientes características: (a) patron pico de difraccion de rayos X comprendiendo picos de 2 theta de aproximadamente 7 degree , 9,7 degree , 10,1 degree , 11,0 degree , 12,4 degree , 13,1 degree , 14,1 degree , 14,6 degree , 15,0 degree , 15,2 degree , 15,8 degree , 16,3 degree , 16,6 degree , 17,6 degree , 18,1 degree , 18,3 degree , 19,7 degree , 20,2 degree , y 21,2 degree ; y (b) un termograma de calorimetría de exploracion diferencial teniendo un pico endotérmico de aproximadamente 188 degree .
ARP050103448A 2004-08-20 2005-08-16 Forma polimorfica de rafampicina AR050374A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60309604P 2004-08-20 2004-08-20

Publications (1)

Publication Number Publication Date
AR050374A1 true AR050374A1 (es) 2006-10-18

Family

ID=35431373

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103448A AR050374A1 (es) 2004-08-20 2005-08-16 Forma polimorfica de rafampicina

Country Status (22)

Country Link
US (1) US7282505B2 (es)
EP (1) EP1781671A1 (es)
JP (1) JP2008510710A (es)
KR (1) KR20070051863A (es)
CN (1) CN101039948A (es)
AR (1) AR050374A1 (es)
AU (1) AU2005277407A1 (es)
BR (1) BRPI0514407A (es)
CA (1) CA2575887A1 (es)
CR (1) CR8929A (es)
EC (1) ECSP077268A (es)
GT (1) GT200500223A (es)
IL (1) IL181170A0 (es)
MX (1) MX2007002044A (es)
NO (1) NO20071050L (es)
PA (1) PA8642501A1 (es)
PE (1) PE20060649A1 (es)
RU (1) RU2007104518A (es)
SV (1) SV2006002201A (es)
TW (1) TW200608973A (es)
WO (1) WO2006023627A1 (es)
ZA (1) ZA200701453B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011000A1 (en) 2002-07-30 2004-02-05 Wyeth Parenteral formulations containing a rapamycin hydroxyester
AU2004274026A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7349971B2 (en) * 2004-02-05 2008-03-25 Scenera Technologies, Llc System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US20060258698A1 (en) 2005-02-09 2006-11-16 Sreenivasu Mudumba Liquid formulations for treatment of diseases or conditions
BRPI0707612B8 (pt) 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
EP2001466B1 (en) 2006-03-23 2016-01-06 Santen Pharmaceutical Co., Ltd Low-dose rapamycin for the treatment of vascular permeability-related diseases
US7820812B2 (en) 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
US7812032B2 (en) 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
MX2009001067A (es) * 2006-07-25 2009-06-17 Abbott Lab Formas cristalinas de analogos de rapamicina.
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
US20080175887A1 (en) * 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US20120064143A1 (en) 2008-11-11 2012-03-15 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
JP5643770B2 (ja) * 2009-01-21 2014-12-17 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ シロリムスの安定性の決定方法およびその安定形態の調製方法
WO2010086863A2 (en) 2009-02-02 2010-08-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Crystalline drug-containing coatings
WO2011049659A2 (en) * 2009-08-05 2011-04-28 The Government Of United States, As Represented By The Secretary Of The Army Novel use and method of rapamycin to treat toxic shock
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US20140343128A1 (en) 2011-11-15 2014-11-20 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the Janus Kinase 2 - Signal Transducer and Activator of Transcription 5 pathway
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
US20160030401A1 (en) 2013-03-13 2016-02-04 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
JP6529012B2 (ja) 2013-10-08 2019-06-12 エイアイ・セラピューティクス・インコーポレーテッド リンパ脈管筋腫症の処置のためのラパマイシン
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
DK3089737T3 (da) 2013-12-31 2021-12-13 Rapamycin Holdings Llc Orale rapamycin-nanopartikelpræparater og anvendelse.
US20150265582A1 (en) * 2014-02-11 2015-09-24 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
WO2015154084A1 (en) 2014-04-04 2015-10-08 Lam Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
CA2963085C (en) 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
CN106478663A (zh) * 2015-08-26 2017-03-08 博瑞生物医药（苏州）股份有限公司 一种依维莫司的干燥方法
WO2018213352A1 (en) 2017-05-15 2018-11-22 C.R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
CN109020995A (zh) * 2017-06-12 2018-12-18 鲁南制药集团股份有限公司 一种替西罗莫司的晶型物
US11541152B2 (en) 2018-11-14 2023-01-03 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
US20220176084A1 (en) 2019-04-08 2022-06-09 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
UA41884C2 (uk) 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів

Also Published As

Publication number Publication date
GT200500223A (es) 2006-03-09
MX2007002044A (es) 2007-03-29
TW200608973A (en) 2006-03-16
KR20070051863A (ko) 2007-05-18
CN101039948A (zh) 2007-09-19
RU2007104518A (ru) 2008-09-27
WO2006023627A8 (en) 2006-11-30
PA8642501A1 (es) 2006-05-16
CA2575887A1 (en) 2006-03-02
EP1781671A1 (en) 2007-05-09
PE20060649A1 (es) 2006-08-10
US20060040971A1 (en) 2006-02-23
CR8929A (es) 2007-08-28
AU2005277407A1 (en) 2006-03-02
BRPI0514407A (pt) 2008-06-10
US7282505B2 (en) 2007-10-16
JP2008510710A (ja) 2008-04-10
NO20071050L (no) 2007-05-15
ZA200701453B (en) 2010-08-25
ECSP077268A (es) 2007-03-29
SV2006002201A (es) 2006-05-09
WO2006023627A1 (en) 2006-03-02
IL181170A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
AR050374A1 (es) Forma polimorfica de rafampicina
AR047994A1 (es) Formas polimorficas de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidin-2,6-diona
AR046124A1 (es) Forma polimorfica de la n-[(r)-2,3-dihidroxipropoxi]-3,4 difluoro-2-(2-fluoro-4-iodofenilamino)benzamida; proceso de obtencion y composiciones farmaceuticas
UY26886A1 (es) Polimorfos de un análogo de epotilona
AR047088A1 (es) Polimorfo cristalino de piridinetilennaftofurano como antagonista del receptor de trombina, metodo de obtencion y composiciones farmaceuticas
AR063347A1 (es) Formas cristalinas de docetaxel y proceso para su preparacion
ECSP088098A (es) Nuevos regímenes para anticonceptivos orales monofásicos
BRPI0500585A (pt) Processo para a sìntese de ivabradina e sais de adição desta com um ácido farmaceuticamente aceitável
AR055054A1 (es) Cristales formados de clorhidrato de (((2r)-7-(2,6-diclorofenil)-5-fluoro-2,3- dihidro-1-benzofurano-2-il) metil ) amina
WO2009070314A3 (en) Crystalline form of sitagliptin
DK1606242T3 (da) Azidfri fremgangsmåde til fremstilling af 1,2-diaminoforbindelser
AR048527A1 (es) Variedades cristalinas de acetato de bazedoxifeno
BRPI0407282A (pt) Processo para preparação de inibidores de pirrolotriazina cinase
WO2006066950A3 (de) Tricyclische aminoalkohole, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
FR2852323B1 (fr) Nouveau procede de reformage regeneratif
UY27903A1 (es) Derivados de indolinona sustituidos en posición 6, su preparación y su uso como medicamentos.
EA200500202A1 (ru) Новый способ синтеза (7-метокси-3,4-дигидро-1-нафталинил)ацетонитрила и его применение при синтезе агомелатина
CR9208A (es) Procesos para la preparacion de alcoholes de aminoetoxibencilo
EP1961733A4 (en) PROCESS FOR SELECTIVELY PREPARING A PRIMARY AMINE COMPOUND
FR2922810B1 (fr) Procede d'etirage d'un film en matiere synthetique se presentant sous la forme d'une bande allongee.
BR0214742A (pt) Polimorfo cristalino de cloridrato de venlafaxina e métodos para sua preparação
ATE449098T1 (de) Stereoselektive synthese bestimmter trifluormethylsubstituierter alkohole
ES2602358T3 (es) Forma polimórfica de N-[4-(trifluorometil)bencil)-4-metoxibutiramida
CO5190663A1 (es) Poliformos de un diclorhidrato cristalino de azobiciclo [2.2.2] oct-3 ilamina y sus composiciones farmaceuticas
SI1845780T1 (sl) Uporaba derivatov metilfenidata

Legal Events

Date Code Title Description
FB Suspension of granting procedure